drugset / Trial / NCT05076591
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2024-12
- Completion
- 2024-12
Outcome
Outcome not reported
Stopped (Business): “Due to a business decision resulting in the deprioritization of this project and with no safety concerns present, we (the trial sponsor) have decided to request the discontinuation of study IMM2902-101.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 0.25 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | VISLARAFUSP ALFA | Monoclonal antibody | 2 mg/kg | Intravenous |